ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.485
0.34%
US Dollar vs AUD
1.49963
0.19%
Bitcoin
66,382.04
1.75%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NextCure Inc (NXTC)

  7. NextCure Inc (NXTC) News

NXTC

NextCure (NXTC)

NextCure Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NXTC
DateTimeSourceHeadlineSymbolCompany
03/05/202406:05GlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
25/04/202406:05GlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
08/04/202421:00GlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/202422:05GlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
02/04/202422:00GlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
21/03/202423:55GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
06/03/202400:05GlobeNewswire Inc.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesNASDAQ:NXTCNextCure Inc
02/02/202408:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/02/202408:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/02/202408:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/02/202408:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/02/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/02/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
19/01/202408:05GlobeNewswire Inc.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersNASDAQ:NXTCNextCure Inc
21/12/202323:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryNASDAQ:NXTCNextCure Inc
14/12/202323:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
14/12/202322:45GlobeNewswire Inc.NextCure Provides Year-End Clinical Pipeline UpdatesNASDAQ:NXTCNextCure Inc
20/11/202323:00GlobeNewswire Inc.NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
16/11/202308:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNASDAQ:NXTCNextCure Inc
03/11/202307:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
03/11/202307:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
03/11/202307:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
17/10/202323:05GlobeNewswire Inc.Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)NASDAQ:NXTCNextCure Inc
27/09/202306:05GlobeNewswire Inc.NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s DiseaseNASDAQ:NXTCNextCure Inc
12/09/202322:05GlobeNewswire Inc.A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLCNASDAQ:NXTCNextCure Inc
08/09/202306:05GlobeNewswire Inc.NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor CollagenNASDAQ:NXTCNextCure Inc
06/09/202306:05GlobeNewswire Inc.Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone DiseaseNASDAQ:NXTCNextCure Inc
31/08/202321:00GlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:NXTCNextCure Inc
05/08/202306:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NXTCNextCure Inc
05/08/202306:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NXTCNextCure Inc
 Showing the most relevant articles for your search:NASDAQ:NXTC

Your Recent History

USOTC
GNCAQ
Genocea Biosciences (CE)
UPBT
PAXUSDT
Pax Dollar
COIN
IPUXBTC
IPUX Token
USOTC
GRLVF
Group Eleven Resource (PK)
LBNK
DOGE2USDT
Dogecoin 2.0
COIN
FIREEEUSD
FireStarter
KOSPI
009835
Hanwha Solutions
LSE
CW.
Cable & Wireless
EU
ICEMU
CS ETF CEMU Inav
LSE
LED
LATK
JCHUSDT
JobCash
COIN
HYDROUST
Hydro
EU
INCE8
Casam Etf CE8 Inav
LSE
AIGS
Wt Softs
NASDAQ
HSOL
EU
APHPK
Assistance Publique Hôp...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved